Evidence map›Paper›PMID 35013352›Full record

ArticleScientific reports2022

Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.

Andrea Dimet-Wiley, Qinglong Wu, Jerrin T Wiley, Aditya Eswar, Harshini Neelakantan, Tor Savidge, Stan Watowich

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Andrea Dimet-WileyDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, USA.ORCID 0000-0003-2214-3670
Qinglong WuDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Jerrin T WileyDepatment of Computer Science, University of Houston, Houston, TX, USA.
Aditya EswarNew York University Stern School of Business, New York City, NY, USA.
Harshini NeelakantanRidgeline Therapeutics, Houston, TX, USA.ORCID 0000-0003-2913-1824
Tor SavidgeDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Stan WatowichDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, USA. watowich@xray.utmb.edu.
Baylor College of Medicine · USThe University of Texas Medical Branch at Galveston · USNew York University · USUniversity of Houston · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO, SAVIDGE, TOR C. · 2020 to 2025
$12.0M
PATHWAYS TO NEW BIOMARKERS IN RECURRENT ABDOMINAL PAIN IN CHILDRENR01NR013497 · NINR · BAYLOR COLLEGE OF MEDICINE · PI SAVIDGE, TOR C. · 2012 to 2024
$4.7M
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetesR41DK119052 · NIDDK · RIDGELINE THERAPEUTICS, LLC · PI WATOWICH, STANLEY · 2018 to 2018
$300k
NIAID NIH HHS P01 AI152999NIA NIH HHS P30 AG024832NIDDK NIH HHS P30 DK056338NIDDK NIH HHS R41 DK119052NIH HHS NIDDK 1R41DK119052-01NIH HHS U01-AI24290NINR NIH HHS R01 NR013497
6 · The paper itself

Abstract

Treatment with a nicotinamide N-methyltransferase inhibitor (NNMTi; 5-amino-1-methylquinolinium) combined with low-fat diet (LD) promoted dramatic whole-body adiposity and weight loss in diet-induced obese (DIO) mice, rapidly normalizing these measures to age-matched lean animals, while LD switch alone was unable to restore these measures to age-matched controls in the same time frame. Since mouse microbiome profiles often highly correlate with body weight and fat composition, this study was designed to test whether the cecal microbiomes of DIO mice treated with NNMTi and LD were comparable to the microbiomes of age-matched lean counterparts and distinct from microbiomes of DIO mice maintained on a high-fat Western diet (WD) or subjected to LD switch alone. There were minimal microbiome differences between lean and obese controls, suggesting that diet composition and adiposity had limited effects. However, DIO mice switched from an obesity-promoting WD to an LD (regardless of treatment status) displayed several genera and phyla differences compared to obese and lean controls. While alpha diversity measures did not significantly differ between groups, beta diversity principal coordinates analyses suggested that mice from the same treatment group were the most similar. K-means clustering analysis of amplicon sequence variants by animal demonstrated that NNMTi-treated DIO mice switched to LD had a distinct microbiome pattern that was highlighted by decreased Erysipelatoclostridium and increased Lactobacillus relative abundances compared to vehicle counterparts; these genera are tied to body weight and metabolic regulation. Additionally, Parasutterella relative abundance, which was increased in both the vehicle- and NNMTi-treated LD-switched groups relative to the controls, significantly correlated with several adipose tissue metabolites' abundances. Collectively, these results provide a novel foundation for future investigations.

Indexed as

Adipose TissueAdiposityAnimalsBacteriaBody WeightCombined Modality TherapyDiet, Fat-RestrictedEnzyme InhibitorsGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred C57BLMice, ObeseNicotinamide N-MethyltransferaseObesityEnzyme InhibitorsNicotinamide N-MethyltransferaseQuinolinium Compounds

Identifiers

PMID35013352
PMCPMC8748953
OpenAlexW4206194498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.